Please wait a minute...
Protein & Cell

ISSN 1674-800X

ISSN 1674-8018(Online)

CN 11-5886/Q

Postal Subscription Code 80-984

2018 Impact Factor: 7.575

Protein Cell    2018, Vol. 9 Issue (10) : 832-837    https://doi.org/10.1007/s13238-017-0503-6
COMMENTARY
IFN-λ: A new spotlight in innate immunity against influenza virus infection
Yeping Sun, Jingwen Jiang, Po Tien, Wenjun Liu(), Jing Li()
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
 Download: PDF(897 KB)  
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Corresponding Author(s): Wenjun Liu,Jing Li   
Issue Date: 18 October 2018
 Cite this article:   
Yeping Sun,Jingwen Jiang,Po Tien, et al. IFN-λ: A new spotlight in innate immunity against influenza virus infection[J]. Protein Cell, 2018, 9(10): 832-837.
 URL:  
https://academic.hep.com.cn/pac/EN/10.1007/s13238-017-0503-6
https://academic.hep.com.cn/pac/EN/Y2018/V9/I10/832
1 Abboud G, Tahiliani V, Desai P, Varkoly K, Driver J, Hutchinson TE, Salek-Ardakani S (2015) Natural killer cells and innate interferon gamma participate in the host defense against respiratory vaccinia virus infection. J Virol 90:129–141
https://doi.org/10.1128/JVI.01894-15
2 Barr IG (2017) Assessing the potential pandemic risk of recent avian influenza viruses. Eur Respir J 49:1602517
https://doi.org/10.1183/13993003.02517-2016
3 Bauer TT, Ewig S, Rodloff AC, Muller EE (2006) Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clin Infect Dis 43:748–756
https://doi.org/10.1086/506430
4 Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FHT, Gerlach T, Malinverni R, Moradpour Det al. (2013) IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 210:1109–1116
https://doi.org/10.1084/jem.20130012
5 Brandes M, Klauschen F, Kuchen S, Germain RN (2013) A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell 154:197–212
https://doi.org/10.1016/j.cell.2013.06.013
6 Broggi A, Tan Y, Granucci F, Zanoni I (2017) IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat Immunol 18:1084–1093
https://doi.org/10.1038/ni.3821
7 Bui CM, Chughtai AA, Adam DC, MacIntyre CR (2017) An overview of the epidemiology and emergence of influenza A infection in humans over time. Arch Public Health 75:15
https://doi.org/10.1186/s13690-017-0182-z
8 Chai N, Swem LR, Park S, Nakamura G, Chiang N, Estevez A, Fong R, Kamen L, Kho E, Reichelt Met al. (2017) A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun 8:14234
https://doi.org/10.1038/ncomms14234
9 Chow KT, Gale M Jr (2015) SnapShot: interferon signaling. Cell 163 (1808–1808):e1801
10 Ciancanelli MJ, Huang SX, Luthra P, Garner H, Itan Y, Volpi S, Lafaille FG, Trouillet C, Schmolke M, Albrecht RAet al. (2015) Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 348:448–453
https://doi.org/10.1126/science.aaa1578
11 Ciancanelli MJ, Abel L, Zhang SY, Casanova JL (2016) Host genetics of severe influenza: from mouse Mx1 to human IRF7. Curr Opin Immunol 38:109–120
https://doi.org/10.1016/j.coi.2015.12.002
12 Dienz O, Rud JG, Eaton SM, Lanthier PA, Burg E, Drew A, Bunn J, Suratt BT, Haynes L, Rincon M (2012) Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol 5:258–266
https://doi.org/10.1038/mi.2012.2
13 Fineberg HV (2014) Pandemic preparedness and response—lessons from the H1N1 influenza of 2009. N Engl J Med 370:1335–1342
https://doi.org/10.1056/NEJMra1208802
14 Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, Thanos D, Doyle SE, Kotenko SV, Thanopoulou Ket al. (2017) Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity 46(875–890):e876
15 Galmozzi E, Vigano M, Lampertico P (2014) Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther 39:569–578
https://doi.org/10.1111/apt.12631
16 Ginsberg J, Mohebbi MH, Patel RS, Brammer L, Smolinski MS, Brilliant L (2009) Detecting influenza epidemics using search engine query data. Nature 457:U1012–U1014
https://doi.org/10.1038/nature07634
17 Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36–49
https://doi.org/10.1038/nri3581
18 Iwasaki A, Pillai PS (2014) Innate immunity to influenza virus infection. Nat Rev Immunol 14:315–328
https://doi.org/10.1038/nri3665
19 Jiang JW, Li J, Fan WH, Zheng WN, Yu M, Chen C, Sun L, Bi YH, Ding C, Gao GFet al. (2016) Robust Lys63-linked ubiquitination of RIG-I promotes cytokine eruption in early influenza B virus infection. J Virol 90:6263–6275
https://doi.org/10.1128/JVI.00549-16
20 Lazear HM, Nice TJ, Diamond MS (2015) Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity 43:15–28
https://doi.org/10.1016/j.immuni.2015.07.001
21 Loo YM, Gale M Jr (2007) Influenza: fatal immunity and the 1918 virus. Nature 445:267–268
https://doi.org/10.1038/445267a
22 Ma W, Huang H, Chen J, Xu K, Dai Q, Yu H, Deng F, Qi X, Wang S, Hong Jet al. (2017) Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013–2016. Influenza Other Respir Viruses 11:418–424
https://doi.org/10.1111/irv.12461
23 Mendoza JL, Schneider WM, Hoffmann HH, Vercauteren K, Jude KM, Xiong A, Moraga I, Horton TM, Glenn JS, de Jong YPet al. (2017) The IFN-lambda-IFN-lambdaR1-IL-10Rbeta complex reveals structural features underlying type III IFN functional plasticity. Immunity 46:379–392
https://doi.org/10.1016/j.immuni.2017.02.017
24 Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, Diamond MS, Virgin HW (2015) Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347:269–273
https://doi.org/10.1126/science.1258100
25 Peiris JS, Cheung CY, Leung CY, Nicholls JM (2009) Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol 30:574–584
https://doi.org/10.1016/j.it.2009.09.004
26 Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin Cet al. (2017) Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients. Front Immunol 8:621
https://doi.org/10.3389/fimmu.2017.00621
27 Poovorawan Y, Pyungporn S, Prachayangprecha S, Makkoch J (2013) Global alert to avian influenza virus infection: from H5N1 to H7N9. Pathog Glob Health 107:217–223
https://doi.org/10.1179/2047773213Y.0000000103
28 Ramsey C, Kumar A (2011) H1N1: viral pneumonia as a cause of acute respiratory distress syndrome. Curr Opin Crit Care 17:64–71
https://doi.org/10.1097/MCC.0b013e3283427259
29 Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513–545
https://doi.org/10.1146/annurev-immunol-032713-120231
30 Short KR, Kroeze E, Fouchier RAM, Kuiken T (2014) Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 14:57–69
https://doi.org/10.1016/S1473-3099(13)70286-X
31 Tate MD, Deng YM, Jones JE, Anderson GP, Brooks AG, Reading PC (2009) Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J Immunol 183:7441–7450
https://doi.org/10.4049/jimmunol.0902497
32 Teijaro JR (2015) The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Curr Top Microbiol Immunol 386:3–22
https://doi.org/10.1007/82_2014_411
33 Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Mur RE, Everson G, Fallon Met al. (2011) Pegylated interferon-Lambda (PEGIFN-lambda) shows superior viral response with improved safety and tolerability versus PEGIFN alpha-2A in HCV patients (G1/2/3/4): emerge phase IIB through week 12. J Hepatol 54:S538–S539
https://doi.org/10.1016/S0168-8278(11)61362-7
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed